Table 2.

Univariate analysis for obtaining protective levels of antibody to COVID-19 infection after two doses of vaccination.

	Univariate analysis
	Odds ratio	95% CI	p
Age > 70 (years)	0.55	0.21–1.44	0.227
MF	0.23	0.07–0.81	0.021
JAK2 mutation	0.94	0.36–2.47	0.904
WBC <6,000 (/μL)	0.51	0.18–1.49	0.223
Lymphocyte <1,000 (/μL)	0.41	0.11–1.47	0.172
Time from diagnosis to vaccination > 6 (years)	0.32	0.12–0.83	0.019
Time from 2nd vaccine to Ab analysis > 40 (days)	0.72	0.28–1.81	0.483
Cytoreductive therapy	1.69	0.67–4.27	0.264
Ruxolitinib	0.08	0.01–0.39	0.001

MF, myelofibrosis; JAK2, Janus kinase 2; WBC, white blood cell; Ab, antibody; CI, confidence interval.